WeVote
Log In

Bill

Bill

HF 2703

Prohibition extended on manufacturers interfering with access to 340B drugs.

2025-2026 Regular Session Introduced by Pete Johnson and 4 co-sponsors

Minnesota bill extends protections preventing drug manufacturers from restricting 340B program discounts for hospitals serving low-income and uninsured patients.

Author stricken Stephenson
#drugsandmedicine
0
WeVote Research Nonpartisan
Bill Summary · HF 2703

Legislative bill overview

HF 2703 extends Minnesota's prohibition on pharmaceutical manufacturers from interfering with hospitals' and healthcare entities' access to discounted drugs under the federal 340B Drug Pricing Program. The bill prevents manufacturers from imposing restrictions, conditions, or penalties on 340B program participants who purchase drugs at reduced rates intended for uninsured and low-income patients.

Why is this important

The 340B program allows qualifying healthcare providers to purchase certain drugs at significant discounts, enabling them to serve more uninsured and vulnerable patients. Manufacturers sometimes circumvent this by limiting supply, imposing arbitrary conditions, or charging penalties to 340B participants, effectively undermining the program's purpose and straining provider budgets for charity care.

Potential points of contention

  • Manufacturer concerns: Pharmaceutical companies may argue restrictions protect against drug diversion and gray market resale, and that 340B discounts already represent substantial revenue loss
  • Program scope debate: Disagreement over which entities qualify for 340B protections and whether the extension adequately defines "interference"
  • Enforcement mechanisms: Unclear how the state would monitor compliance and penalize manufacturers without federal coordination, potentially creating jurisdictional conflicts

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.